<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TEKTURNA HCT - aliskiren hemifumarate and hydrochlorothiazide tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use </span><span class="Bold">Tekturna</span><span class="Bold"> </span><span class="Bold">HCT </span><span class="Bold">safely and effectively. </span><span class="Bold">See full prescribing information for</span><span class="Bold"> </span><span class="Bold">Tekturna</span><span class="Bold"> </span><span class="Bold">HCT</span><span class="Bold">.</span><br><span class="Bold">Tekturna</span><span class="Bold"> </span><span class="Bold">HCT</span><span class="Bold"> (aliskiren and </span><span class="Bold">hydrochlorothiazide)</span><span class="Bold"> </span><span class="Bold">T</span><span class="Bold">ablets</span><br><span class="Bold">Initial U.S. Approval:</span><span class="Bold"> </span><span class="Bold">2008</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING</span><span class="Bold">: </span><span class="Bold">AVOID </span><span class="Bold">USE</span><span class="Bold"> IN PREGNANCY</span>
</h1>
<h1 class="Warning">
<span class="Bold">When pregnancy is detected, discontinue </span><span class="Bold">Tekturna</span><span class="Bold"> </span><span class="Bold">HCT as soon as possible. </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1)</span>
</h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage (1)
		     
	
		     
	
		     
	
		     
	
		     
	07/2009 </p>
<p class="Highlighta">Dosage and Administration </p>
<p class="Highlighta">
		     
	Add-On Therapy (2.3)
		     
	
		     
	
		     
	
		     
	
		     
	07/2009 </p>
<p class="Highlighta">
		     
	Replacement Therapy (2.4)
		     
	
		     
	
		     
	
		     
	
		     
	07/2009 </p>
<p class="Highlighta">
		     
	Initial Therapy (2.5)
		     
	
		     
	
		     
	
		     
	
		     
	07/2009 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING</span><span class="Bold">: </span><span class="Bold">AVOID </span><span class="Bold">USE</span><span class="Bold"> IN PREGNANCY</span>
</h1>
<h1 class="Warning">
<span class="Bold">When pregnancy is detected, discontinue </span><span class="Bold">Tekturna</span><span class="Bold"> </span><span class="Bold">HCT as soon as possible. </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1)</span>
</h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Tekturna HCT<span class="Sup"> </span>is a combination of aliskiren, a direct renin inhibitor, and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>:  (<a href="#section-1">1</a>)</p>
<ul class="Disc">
<li>In patients not adequately controlled with monotherapy<br>
</li>
<li>As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (1)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>The antihypertensive effect is largely manifested within 1 week, with maximal effects seen at around 4 weeks. If blood pressure remains uncontrolled after 2 to 4 weeks of therapy, titrate up to a maximum of 300/25 mg. (2.2)<br>
</li>
<li>Order of increasing mean effect: 150/12.5 mg, 150/25 mg or 300/12.5 mg, and 300/25 mg (2.1)<br>
</li>
<li>One tablet daily, with a routine pattern with regard to meals. (2.7)<br>
</li>
<li>May be administered with other antihypertensive agents. (2.6)<br>
</li>
<li>Add-on or Initial therapy: Initiate with 150/12.5mg. Titrate as needed up to a maximum of 300/25 mg. (2.3, 2.5)<br>
</li>
<li>Replacement therapy: May be substituted for titrated components (2.4)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets (mg aliskiren/mg HCTZ): 150/12.5, 150/25, 300/12.5, 300/25 (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span> (4)  (<a href="#section-4">4</a>)</p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to sulfonamide-derived drugs (4)  (<a href="#section-4">4</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>: Discontinue Tekturna HCT and monitor until signs and symptoms resolve. (5.2)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- or Salt-Depleted Patients: Correct imbalances before initiating therapy with Tekturna HCT. (5.3)<br>
</li>
<li>Patients with Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Not recommended if GFR &lt;30 mL/min. (5.4)<br>
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Titrate slowly. (5.5)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: May occur from HCTZ component (5.6)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence ≥1.5% and more common than with placebo) are: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Aliskiren:</span>  (<a href="#section-7">7</a>)</p>
<ul class="Disc"><li>Cyclosporine: Concomitant use is not recommended.</li></ul>
<p class="Highlighta"><span class="Bold">Hydrochlorothiazide:</span>  (<a href="#section-7">7</a>)</p>
<ul class="Disc">
<li>Alcohol, Barbiturates, Narcotics: Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span><br>
</li>
<li>Antidiabetic Drugs: Dosage adjustment of antidiabetic may be required<br>
</li>
<li>Cholestyramine and Colestipol: Reduced absorption of thiazides<br>
</li>
<li>Corticosteroids, ACTH: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span><br>
</li>
<li>Lithium: Reduced renal clearance and high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> when used with diuretics. Should not be given with diuretics.<br>
</li>
<li>NSAIDs: Can reduce diuretic, natriuretic, and antihypertensive effects of diuretics. Observe patient closely.</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="Bold">Nursing Mothers:</span> Nursing or drug should be discontinued. (8.3)  (<a href="#section-8">8</a>)</p></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREG</span><span class="Bold">NANCY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span><span class="Bold"> </span><span class="Bold">INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold"> </span><span class="Bold">DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 </span><span class="Bold">Dose Selection</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Dose Titration</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.</span><span class="Bold">3 Add-On Therapy</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 Replacement Therapy</span></a></h2>
<h2><a href="#section-2.5" class="toc"><span class="Bold">2.5 Initial Therapy</span></a></h2>
<h2><a href="#section-2.6" class="toc"><span class="Bold">2.</span><span class="Bold">6</span><span class="Bold"> Use with Other Antihypertensive Drugs</span></a></h2>
<h2><a href="#section-2.7" class="toc"><span class="Bold">2.</span><span class="Bold">7</span><span class="Bold"> Relationship to Meals</span></a></h2>
<h2><a href="#section-2.8" class="toc"><span class="Bold">2.</span><span class="Bold">8</span><span class="Bold"> Dosing in Specific Populations</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.</span><span class="Bold">3</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span><span class="Bold"> in Volume- and/or Salt-Depleted</span><span class="Bold"> </span><span class="Bold">Patients</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Patients with Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.</span><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.</span><span class="Bold">6</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><span class="Bold"> Reaction</span><span class="Bold">s</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.</span><span class="Bold">7</span><span class="Bold"> Systemic</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">Lupus Erythematosus</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.</span><span class="Bold">8</span><span class="Bold"> Lithium</span><span class="Bold"> Interaction</span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.</span><span class="Bold">9</span><span class="Bold"> Serum</span><span class="Bold"> Electrolyte</span><span class="Bold"> Abnormalitie</span><span class="Bold">s</span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">Renal Artery Stenosis</span></span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11 Cyclosporine</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span><span class="Bold"> </span><span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 </span><span class="Bold">Clinical Studies Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Clinical Laboratory Test </span><span class="Bold">Abnormalities</span></a></h2>
<h2><a href="#section-6.3" class="toc"><span class="Bold">6.3  Post-</span><span class="Bold">M</span><span class="Bold">arketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span><span class="Bold"> </span><span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold"> </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 </span><span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.</span><span class="Bold">3</span><span class="Bold"> </span><span class="Bold">Nursing Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.</span><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.</span><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold"> </span><span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span><span class="Bold"> </span><span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold"> </span><span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span><span class="Bold"> </span><span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span><span class="Bold"> </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span><span class="Bold"> </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17</span><span class="Bold"> </span><span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREG</span><span class="Bold">NANCY</span>
</h1>
<p class="First"><span class="Bold">When pregnancy is detected, discontinue </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold"><span class="Sup"> </span></span><span class="Bold">as soon as possible. </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span><span class="Bold Italics"> </span><span class="Bold">[</span><span class="Bold Italics">See Warnings and Precautions</span><span class="Bold Italics"> (5.1)</span><span class="Bold">]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold"> </span><span class="Bold">INDICATIONS AND USAGE</span>
</h1>
<p class="First">Tekturna HCT is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><span class="Italics Underline">Add-On Therapy</span></p>
<p>A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT.</p>
<p>A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may be switched to combination therapy with Tekturna HCT.</p>
<p>A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT<span class="Sup"> </span>containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions.</p>
<p><span class="Italics Underline">Replacement Therapy</span></p>
<p>Tekturna HCT may be substituted for the titrated components.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics Underline">Initial Therapy</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. </span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients with Stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> are at a relatively high risk for cardiovascular events (such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Data from the high-dose multifactorial study [<span class="Italics">see Clinical Studies (14)</span>] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. </span></p>
<div class="Figure">
<img alt="Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) &lt;140 mmHg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=tekturna-hct-01.jpg"><p class="MultiMediaCaption">Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) &lt;140 mmHg</p>
</div>
<div class="Figure">
<img alt="Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) &lt;130 mmHg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=tekturna-hct-02.jpg"><p class="MultiMediaCaption">Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) &lt;130 mmHg</p>
</div>
<div class="Figure">
<img alt="Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) &lt;90 mmHg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=tekturna-hct-03.jpg"><p class="MultiMediaCaption">Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) &lt;90 mmHg</p>
</div>
<div class="Figure">
<img alt="Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) &lt;80 mmHg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=tekturna-hct-04.jpg"><p class="MultiMediaCaption">Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) &lt;80 mmHg</p>
</div>
<p style="border-left:1px solid;"><span class="XmChange">At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of &lt;140 mmHg (systolic) and<span class="Bold"> </span>61% chance of achieving &lt;90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and<span class="Bold"> </span>37% (diastolic). <span class="Italics">[See Dosage and Administration (2) and Clinical Studies (14)</span><span class="Italics">.</span><span class="Italics">]</span></span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold"> </span><span class="Bold">DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1 </span><span class="Bold">Dose Selection</span>
</h2>
<p class="First">The recommended once-daily doses of Tekturna HCT in order of increasing mean effect are 150/12.5 mg, 150/25 mg or 300/12.5 mg, and 300/25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Dose Titration</span></h2>
<p class="First">The antihypertensive effect of Tekturna HCT is largely manifested within 1 week, with maximal effects generally seen at around 4 weeks. If blood pressure remains uncontrolled after 2 to 4 weeks of therapy, the dose may be titrated up to a maximum of aliskiren 300 mg/hydrochlorothiazide 25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">3 Add-On Therapy</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. The usual recommended starting dose is 150/12.5 mg once daily as needed to control blood pressure. The dose may be titrated up to a maximum of aliskiren 300 mg/hydrochlorothiazide 25 mg once daily.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 Replacement Therapy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Tekturna HCT may be substituted for the individually titrated components.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.5"></a><p></p>
<h2><span class="Bold">2.5 Initial Therapy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The usual recommended starting dose is 150/12.5 mg once daily as needed to control blood pressure. The dose may be titrated up to a maximum of aliskiren 300 mg/hydrochlorothiazide 25 mg once daily.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Tekturna HCT is not recommended for use as initial therapy in patients with intravascular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>. <span class="Italics">[See Warnings and Precautions (5.3)]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">6</span><span class="Bold"> Use with Other Antihypertensive Drugs</span>
</h2>
<p class="First">Tekturna HCT may be administered with other antihypertensive agents. There are no data available with use of Tekturna HCT with angiotensin-converting enzyme inhibitors or beta blockers [<span class="Italics">s</span><span class="Italics">ee Clinical Studies (14)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.7"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">7</span><span class="Bold"> Relationship to Meals</span>
</h2>
<p class="First">Patients should establish a routine pattern for taking Tekturna HCT<span class="Sup"> </span>with regard to meals. High-fat meals decrease absorption substantially <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee </span><span class="Italics">Clinical Pharmacology </span><span class="Italics">(12.3)]</span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.8"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">8</span><span class="Bold"> Dosing in Specific Populations</span>
</h2>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The usual regimens of Tekturna HCT may be followed as long as the patient’s creatinine clearance is &gt;30 mL/min. In patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, loop diuretics are preferred to thiazides, so Tekturna HCT is not recommended.</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Adjustment of the starting dose is not necessary with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Italics Underline">Elderly Patients</span></p>
<p>Adjustment of the starting dose is not required for elderly patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<ul class="Disc">
<li>150 mg/12.5 mg tablets: white, biconvex ovaloid, film-coated tablets imprinted with NVR/LCI<br>
</li>
<li>150 mg/25 mg tablets: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, biconvex ovaloid, film-coated tablets imprinted with NVR/CLL<br>
</li>
<li>300 mg/12.5 mg tablets: violet white, biconvex ovaloid, film-coated tablets imprinted with NVR/CVI<br>
</li>
<li>300 mg/25 mg tablets: light yellow, biconvex ovaloid, film-coated tablets imprinted with NVR/CVV</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span><span class="Bold"> </span><span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">Because of the hydrochlorothiazide component, Tekturna HCT is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulfonamide-derived drugs [<span class="Italics">s</span><span class="Italics">ee Warnings and Precautions (5.6)</span><span class="Italics"> and Adverse Reactions (6.1)</span>]. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may range from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> [<span class="Italics">s</span><span class="Italics">ee Adverse Reactions (6.1)</span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span><span class="Bold"> </span><span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span>
</h2>
<p class="First">Tekturna HCT can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered to pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus. <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Use in Specific Populations (8.1)]</span> In several dozen published cases, ACE inhibitors use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In addition, first trimester use of ACE inhibitors has been associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Thiazides cross the placenta, and use of thiazides during pregnancy is associated with a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possible other adverse reactions that have occurred in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></h2>
<p class="First"><span class="Italics Underline">Aliskiren</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with  Tekturna and has necessitated hospitalization and intubation. This may occur at any time during treatment and has occurred in patients with and without a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with ACE inhibitors or angiotensin receptor antagonists. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the throat, tongue, glottis or larynx, or if the patient has a history of upper respiratory surgery, airway obstruction may occur and be fatal.  Patients who experience these effects, even without <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. Prompt administration of subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 ml) and measures to ensure a patient airway may be necessary.</p>
<p>Discontinue Tekturna immediately in patients who develop <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and do not readminister.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">3</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span><span class="Bold"> in Volume- and/or Salt-Depleted</span><span class="Bold"> </span><span class="Bold">Patients</span>
</h2>
<p class="First">An excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) was rarely seen (&lt;1%) in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with Tekturna HCT in controlled trials. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur. Correct these conditions prior to administration of Tekturna HCT, or the treatment should start under close medical supervision.</p>
<p>If an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> occurs, place the patient in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Patients with Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First"><span class="Italics Underline">Tekturna </span><span class="Italics Underline">HCT</span></p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;30 mL/min), loop diuretics are preferred to thiazides, so Tekturna HCT is not recommended.</p>
<p><span class="Italics Underline">H</span><span class="Italics Underline">ydrochlorothiazide</span></p>
<p>Uptitrate slowly;in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>
</h2>
<p class="First"><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p>Uptitrate slowly; minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">6</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><span class="Bold"> Reaction</span><span class="Bold">s</span>
</h2>
<p class="First"><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">7</span><span class="Bold"> Systemic</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">Lupus Erythematosus</span></span>
</h2>
<p class="First"><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p>Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">8</span><span class="Bold"> Lithium</span><span class="Bold"> Interaction</span>
</h2>
<p class="First"><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p>Lithium generally should not be given with thiazides <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Drug Interaction</span><span class="Italics"> </span><span class="Italics">(7)</span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">9</span><span class="Bold"> Serum</span><span class="Bold"> Electrolyte</span><span class="Bold"> Abnormalitie</span><span class="Bold">s</span>
</h2>
<p class="First"><span class="Italics Underline">Tekturna </span><span class="Italics Underline">HCT</span></p>
<p>In the short-term controlled trials of various doses of Tekturna HCT the incidence of hypertensive patients who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 mEq/L) was 2.2%; the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.5 mEq/L) was 0.8%. No patients discontinued due to increase or decrease of serum potassium.</p>
<p>Periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals. The intervals should be based on the history of electrolyte abnormalities in patients with aliskiren or hydrochlorothiazide monotherapy.</p>
<p>Based on experience with the use of other substances that affect the renin-angiotensin system (RAS), concomitant use of Tekturna HCT with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other drugs that increase potassium levels may lead to increases in serum potassium. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.10"></a><p></p>
<h2>
<span class="Bold">5.10</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">Renal Artery Stenosis</span></span>
</h2>
<p class="First">No data are available on the use of Tekturna HCT in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span> or stenosis of the artery to a solitary kidney.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.11"></a><p></p>
<h2><span class="Bold">5.11 Cyclosporine</span></h2>
<p class="First"><span class="Italics Underline">Aliskiren</span></p>
<p>When aliskiren was given with cyclosporine, the blood concentrations of aliskiren were significantly increased. Concomitant use of aliskiren with cyclosporine is not recommended <span class="Italics">[see Drug Interactions (7)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span><span class="Bold"> </span><span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1 </span><span class="Bold">Clinical Studies Experience</span>
</h2>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul class="Disc">
<li>Risk of fetal/neonatal morbidity and mortality <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee Warnings and Precautions (5.1)]</span><br>
</li>
<li>Head and neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee Warnings and Precautions (5.2)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in volume- and/or salt-depleted patients <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee Warnings and Precautions (5.3)]</span>
</li>
</ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics Underline">Tekturna</span><span class="Italics Underline"> </span><span class="Italics Underline">HCT</span></p>
<p>Tekturna HCT has been evaluated for safety in more than 2,700 patients, including over 700 treated for 6 months and 190 for over 1 year. In placebo-controlled clinical trials, discontinuation of therapy due to a clinical adverse event (including <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>) occurred in 2.7% of patients treated with Tekturna HCT versus 3.6% of patients given placebo.</p>
<p>Adverse events in placebo-controlled trials that occurred in at least 1% of patients treated with Tekturna HCT and at a higher incidence than placebo included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.3% vs. 1%), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> (2.3% vs. 1.6%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1.6% vs. 0.5%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (1.3% vs. 0.5%), <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (1.2% vs. 0.5%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (1.2% vs. 0%), and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (1% vs. 0.5%).</p>
<p><span class="Italics Underline">A</span><span class="Italics Underline">liskiren</span></p>
<p>Aliskiren has been evaluated for safety in 6,460 patients, including 1,740 treated for longer than 6 months, and 1,250 for longer than 1 year. In placebo-controlled clinical trials, discontinuation of therapy due to a clinical adverse event, including uncontrolled hypertension occurred in 2.2% of patients treated with aliskiren, versus 3.5% of patients given placebo.</p>
<p>Two cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with respiratory symptoms were reported with aliskiren use in the clinical studies. Two other cases of <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span> without respiratory symptoms were reported as possible <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and resulted in discontinuation. The rate of these <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> cases in the completed studies was 0.06%.</p>
<p>In addition, 26 other cases of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> involving the face, hands, or whole body were reported with aliskiren use, including 4 leading to discontinuation.</p>
<p>In the placebo-controlled studies, however, the incidence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> involving the face, hands, or whole body was 0.4% with aliskiren compared with 0.5% with placebo. In a long-term active-controlled study with aliskiren and HCTZ arms, the incidence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> involving the face, hands, or whole body was 0.4% in both treatment arms.</p>
<p>Aliskiren produces dose-related gastrointestinal (GI) adverse reactions. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was reported by 2.3% of patients at 300 mg, compared to 1.2% in placebo patients. In women and the elderly (age ≥65) increases in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> rates were evident starting at a dose of 150 mg daily, with rates for these subgroups at 150 mg comparable to those seen at 300 mg for men or younger patients (all rates about 2% to 2.3%). Other GI symptoms included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, although increased rates for <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> were distinguished from placebo only at 600 mg daily. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and other GI symptoms were typically mild and rarely led to discontinuation.</p>
<p>Aliskiren was associated with a slight increase in <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in the placebo-controlled studies (1.1% for any aliskiren use vs. 0.6% for placebo). In active-controlled trials with ACE inhibitor (ramipril, lisinopril) arms, the rates of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> for the aliskiren arms were about one-third to one-half the rates in the ACE inhibitor arms.</p>
<p>Other adverse reactions with increased rates for aliskiren compared to placebo included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1% vs. 0.3%), elevated uric acid (0.4% vs. 0.1%), <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> (0.2% vs. 0.1%), and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> (0.2% vs. 0%).</p>
<p>Single episodes of tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> with <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> were reported in two patients treated with aliskiren in the clinical trials. One patient had predisposing causes for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and had a negative electroencephalogram (EEG) and cerebral imaging following the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; for the other patient, EEG and imaging results were not reported. Aliskiren was discontinued and there was no rechallenge in either case.</p>
<p>The following adverse events occurred in placebo-controlled clinical trials at an incidence of more than 1% of patients treated with aliskiren, but also occurred at about the same or greater incidence in patients receiving placebo: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
<p>No clinically meaningful changes in vital signs or in ECG (including QTc interval) were observed in patients treated with aliskiren.</p>
<p><span class="Italics Underline">H</span><span class="Italics Underline">ydrochlorothiazide</span></p>
<p>Other adverse reactions that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold Italics">B</span><span class="Bold Italics">ody As A Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Bold Italics">Digestive:</span><span class="Italics"> </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span></p>
<p><span class="Bold Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>;</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></p>
<p><span class="Bold Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></p>
<p><span class="Bold Italics">Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p>
<p><span class="Bold Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Bold Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p><span class="Bold Italics">Special Senses:</span> transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.2 Clinical Laboratory Test </span><span class="Bold">Abnormalities</span>
</h2>
<p class="First">In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Tekturna HCT.</p>
<p><span class="Italics Underline">B</span><span class="Italics Underline">lood </span><span class="Italics Underline">Urea N</span><span class="Italics Underline">itrogen (BUN)/Creatinine:</span><span class="Italics"> </span>Elevations (greater than 50% increase) in BUN and creatinine occurred in 11.8% and 0.9%, respectively, of patients taking Tekturna HCT, and 7% and 1.1%, respectively, of patients given placebo in short-term controlled clinical trials. No patients were discontinued due to an increase in either BUN or creatinine.</p>
<p><span class="Italics Underline">H</span><span class="Italics Underline">emoglobin and Hematocrit:</span><span class="Italics"> </span>A greater than 20% decrease in hemoglobin and hematocrit were observed in &lt;0.1% and 0.1%, respectively, of patients treated with Tekturna HCT, compared with 0% in placebo-treated patients. No patients were discontinued due to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p><span class="Italics Underline">L</span><span class="Italics Underline">iver Function T</span><span class="Italics Underline">ests:</span><span class="Italics"> </span>Occasional elevations (greater than 150%) in ALT (SGPT) were observed in 1.2% of patients treated with Tekturna HCT, compared with 0% in placebo-treated patients. No patients were discontinued due to <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>.</p>
<p><span class="Italics Underline">S</span><span class="Italics Underline">erum Uric Acid:</span><span class="Italics"> </span>Uric acid related abnormalities were more commonly observed in patients treated with Tekturna HCT, compared with placebo; 2.2% versus 0% had a uric acid increase &gt;50% from baseline; <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> were less commonly observed.</p>
<p><span class="Italics Underline">S</span><span class="Italics Underline">erum Electrolytes:</span><span class="Italics"> </span><span class="Italics">[</span><span class="Italics">See Warnings</span><span class="Italics"> and </span><span class="Italics">Precautions</span><span class="Italics"> (5.</span><span class="Italics">8</span>)<span class="Italics">.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>
<span class="Bold">6.3  Post-</span><span class="Bold">M</span><span class="Bold">arketing Experience</span>
</h2>
<p class="First">The following adverse reactions have been reported in aliskiren post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> requiring airway management and hospitalization</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span><span class="Bold"> </span><span class="Bold">DRUG INTERACTIONS</span>
</h1>
<p class="First">No drug interaction studies have been conducted with Tekturna HCT and other drugs, although studies with the individual aliskiren and hydrochlorothiazide components are described below.</p>
<p><span class="Bold">Aliskiren</span></p>
<p><span class="Italics Underline">Effects </span><span class="Italics Underline">of Other Drugs </span><span class="Italics Underline">on Aliskiren</span></p>
<p>Based on in vitro studies, aliskiren is metabolized by CYP 3A4.</p>
<p><span class="Italics">Irbesartan:</span> Coadministration of irbesartan reduced aliskiren C<span class="Sub">max</span> up to 50% after multiple dosing.</p>
<p><span class="Italics">P-glycoprotein Effects:</span> Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies. The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter. Coadministration of aliskiren with Pgp substrates or weak to moderate inhibitors such as atenolol, digoxin, and amlodipine did not result in clinically relevant interactions.</p>
<p><span class="Italics">Atorvastatin:</span> Coadministration of atorvastatin, a weak Pgp inhibitor, resulted in about a 50% increase in aliskiren C<span class="Sub">max</span> and AUC after multiple dosing.</p>
<p><span class="Italics">Ketoconazole:</span> Coadministration of 200 mg twice-daily ketoconazole, a moderate Pgp inhibitor, with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren. A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.</p>
<p><span class="Italics">Cyclosporine:</span> Coadministration of 200 mg and 600 mg cyclosporine, a potent Pgp inhibitor, with 75 mg aliskiren resulted in an approximately 2.5-fold increase in C<span class="Sub">max</span> and 5-fold increase in AUC of aliskiren. Concomitant use of aliskiren with cyclosporine is not recommended.</p>
<p><span class="Italics">Verapamil:</span>  Coadministration of 240 mg of verapamil, a moderate Pgp inhibitor, with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.</p>
<p><span class="Italics">Drugs with no clinically significant effects:</span> Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.</p>
<p><span class="Italics Underline">Effects of Aliskiren on Other Drugs</span></p>
<p>Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.</p>
<p><span class="Italics">Furosemide:</span> When aliskiren was coadministered with furosemide, the AUC and C<span class="Sub">max</span> of furosemide were reduced by about 30% and 50%, respectively. Patients receiving furosemide could find its effect diminished after starting aliskiren.</p>
<p><span class="Italics">Drugs with no clinically significant effects:</span> Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.</p>
<p><span class="Italics">Warfarin</span><span class="Italics">:</span> The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>When administered concurrently, the following drugs may interact with thiazide diuretics.</p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics</span><span class="Italics">:</span> Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Antidiabetic drugs (oral agents and insulin</span><span class="Italics">)</span><span class="Italics">:</span> Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Other antihypertensive drugs</span><span class="Italics">:</span> Additive effect or potentiation.</p>
<p><span class="Italics">Cholestyramine and colestipol resins</span><span class="Italics">:</span> Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.</p>
<p><span class="Italics">Corticosteroids, ACTH</span><span class="Italics">:</span> Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Pressor amines</span> <span class="Italics">(e.g., norepinephrine</span><span class="Italics">)</span><span class="Italics">:</span> Possible decreased response to pressor amines but not sufficient to preclude their use.</p>
<p><span class="Italics">Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine</span><span class="Italics">)</span><span class="Italics">:</span> Possible increased responsiveness to the muscle relaxants.</p>
<p><span class="Italics">Lithium</span><span class="Italics">:</span> Should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium before use of such preparation with Tekturna HCT.</p>
<p><span class="Italics">Nonsteroidal anti-inflammatory </span><span class="Italics">d</span><span class="Italics">rugs</span><span class="Italics">:</span> In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Tekturna HCT and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold"> </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1 </span><span class="Bold">Pregnancy</span>
</h2>
<p class="First">Pregnancy Category D<span class="Italics"> </span><span class="Italics">[</span><span class="Italics">See Warnings and Precautions</span><span class="Italics"> (5.1)</span><span class="Italics">.</span><span class="Italics">]</span></p>
<p>Tekturna HCT contains both aliskiren (a direct renin inhibitor) and hydrochlorothiazide (a thiazide diuretic). When administered during the second or third trimester of pregnancy, drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Thiazides can cross the placenta, and use of thiazides during pregnancy is associated with a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults. Tekturna HCT can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus.</p>
<p>In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Oligohydramnios was also reported, presumably from decreased fetal renal function. In this setting, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> was associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> were also reported, although it is not clear whether these occurrences were due to exposure to the drug. In addition, first trimester use of ACE inhibitors, a specific class of drugs acting on the renin-angiotensin system, has been associated with a potential risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in retrospective data.</p>
<p>When pregnancy occurs in a patient using Tekturna HCT, the physician should discontinue Tekturna HCT treatment as soon as possible. The physician should inform the patient about potential risks to the fetus based on the time of gestational exposure to Tekturna HCT (first trimester only or later). If exposure occurs beyond the first trimester, an ultrasound examination should be done.</p>
<p>In rare cases when another antihypertensive agent cannot be used to treat the pregnant patient, serial ultrasound examinations should be performed to assess the intraamniotic environment. Routine fetal testing with non-stress tests, biophysical profiles, and/or contraction stress tests may be appropriate based on gestational age and standards of care in the community. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> occurs in these situations, individualized decisions about continuing or discontinuing Tekturna HCT treatment and about pregnancy management should be made by the patient, her physician, and experts in the management of high risk pregnancy. Patients and physicians should be aware that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Infants with histories of in utero<span class="Italics"> </span>exposure to Tekturna HCT should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, these infants may require blood pressure and renal perfusion support. Exchange transfusion or dialysis may be required to reverse <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or support decreased renal function.</p>
<p>No reproductive toxicity studies have been conducted with the combination of aliskiren and hydrochlorothiazide. However, these studies have been conducted for aliskiren as well as hydrochlorothiazide alone.</p>
<p>Reproductive toxicity studies of aliskiren hemifumarate did not reveal any evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at oral doses up to 600 mg aliskiren/kg/day (20 times the maximum recommended human dose [MRHD] of 300 mg/day on a mg/m<span class="Sup">2</span> basis) in pregnant rats or up to 100 mg aliskiren/kg/day (seven times the MRHD on a mg/m<span class="Sup">2</span> basis) in pregnant rabbits. Fetal birth weight was adversely affected in rabbits at 50 mg/kg/day (3.2 times the MRHD on a mg/m<span class="Sup">2 </span>basis). Aliskiren was present in placenta, amniotic fluid and fetuses of pregnant rabbits.</p>
<p>When pregnant mice and rats were given hydrochlorothiazide at doses up to 3000 and 1000 mg/kg/day, respectively (about 600 and 400 times the MRHD) during their respective periods of major organogenesis, there was no evidence of fetal harm.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">3</span><span class="Bold"> </span><span class="Bold">Nursing Mothers</span>
</h2>
<p class="First">It is not known whether aliskiren is excreted in human milk, but aliskiren was secreted in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">Pediatric Use</span>
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">Geriatric Use</span>
</h2>
<p class="First">In the short-term controlled clinical trials of Tekturna HCT, 325 (19.6%) patients treated with Tekturna HCT were ≥65 years and 53 (3.2%) were ≥75 years.</p>
<p>No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold"> </span><span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First"><span class="Italics Underline">Aliskiren</span></p>
<p>Limited data are available related to overdosage in humans. The most likely manifestation of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be initiated.</p>
<p><span class="Italics Underline">H</span><span class="Italics Underline">ydrochlorothiazide</span></p>
<p>The most common signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> observed in humans are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold"> </span><span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">Tekturna HCT is a fixed combination of aliskiren, an orally active, nonpeptide, direct renin inhibitor, and hydrochlorothiazide, a thiazide diuretic.</p>
<p><span class="Italics Underline">A</span><span class="Italics Underline">liskiren</span></p>
<p>Aliskiren hemifumarate is chemically described as (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate and its structural formula is</p>
<p><img alt="Aliskiren Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=tekturna-hct-05.jpg"></p>
<p>Molecular formula: C<span class="Sub">30</span>H<span class="Sub">53</span>N<span class="Sub">3</span>O<span class="Sub">6</span> • 0.5 C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span></p>
<p>Aliskiren hemifumarate is a white to slightly yellowish crystalline powder with a molecular weight of 609.8 (free base- 551.8). It is soluble in phosphate buffer, n-Octanol, and highly soluble in water.</p>
<p><span class="Italics Underline">H</span><span class="Italics Underline">ydrochlorothiazide</span></p>
<p>Hydrochlorothiazide USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in <span class="Italics">n</span>-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>, its molecular weight is 297.73, and its structural formula is</p>
<p>
		     
	</p>
<p>
		     
	<img alt="Hydrochlorothiazide Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=tekturna-hct-06.jpg"></p>
<p>
		     
	</p>
<p>Tekturna HCT<span class="Bold"> </span>tablets are formulated for oral administration to contain aliskiren and hydrochlorothiazide, USP 150/12.5 mg, 150/25 mg, 300/12.5 mg and 300/25 mg. The inactive ingredients for all strengths of the tablets are colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxide colorants, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, talc, titanium dioxide, and wheat starch.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold"> </span><span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span>
</h2>
<p class="First"><span class="Italics Underline">Aliskiren</span></p>
<p>Renin is secreted by the kidney in response to decreases in blood volume and renal perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.</p>
<p>All agents that inhibit the RAAS, including renin inhibitors, suppress the negative feedback loop, leading to a compensatory rise in plasma renin concentration. When this rise occurs during treatment with ACE inhibitors and ARBs, the result is increased levels of PRA. During treatment with aliskiren, however, the effect of increased renin levels is blocked, so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.</p>
<p><span class="Italics Underline">H</span><span class="Italics Underline">ydrochlorothiazide</span></p>
<p>Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of agents that block the production or function of angiotensin II tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of action of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span>
</h2>
<p class="First"><span class="Italics Underline">Tekturna </span><span class="Italics Underline">HCT</span></p>
<p>In placebo-controlled clinical trials, PRA was decreased with aliskiren monotherapy (ranging from 54% to 65%) and increased with hydrochlorothiazide monotherapy (ranging from 4% to 72%). Treatment with Tekturna HCT resulted in PRA reductions ranging from approximately 46% to 63% in various doses despite the increase in PRA with hydrochlorothiazide treatment. The clinical implications of the differences in effect on PRA are not known.</p>
<p><span class="Italics Underline">Aliskiren</span></p>
<p>PRA reductions in clinical trials ranged from approximately 50% to 80%, were not dose-related and did not correlate with blood pressure reductions. The clinical implications of the differences in effect on PRA are not known.</p>
<p><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p>After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours, and lasts about 6 to 12 hours.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span>
</h2>
<p class="First"><span class="Italics Underline">Absorption</span><span class="Italics Underline"> and Distribution</span></p>
<p><span class="Italics">Tekturna </span><span class="Italics">HCT</span></p>
<p>Following oral administration of Tekturna HCT combination tablets, the median peak plasma concentration time are within 1 hour for aliskiren and 2.5 hours for hydrochlorothiazide. When taken with food, mean AUC and C<span class="Sub">max</span> of aliskiren are decreased by 60% and 82%, respectively; mean AUC and C<span class="Sub">max</span> of hydrochlorothiazide increased by 13% and 10%, respectively. As a result, patients should establish a routine pattern for taking Tekturna HCT with regard to meals and should be advised that high-fat meals decrease absorption of aliskiren substantially.</p>
<p><span class="Italics">H</span><span class="Italics">ydrochlorothiazide</span></p>
<p>Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
<p><span class="Italics Underline">Metabolism and Elimination</span></p>
<p><span class="Italics">Aliskiren</span></p>
<p>About one-fourth of the absorbed dose appears in the urine as parent drug. How much of the absorbed dose is metabolized is unknown. Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP 3A4.</p>
<p><span class="Italics">Hydrochlorothiazide</span></p>
<p>Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated as unchanged drug within 24 hours. The elimination half-life is between 5.8 and 18.9 hours.</p>
<p><span class="Italics Underline">Special Populations</span></p>
<p><span class="Italics">P</span><span class="Italics">ediatri</span><span class="Italics">c Patients</span></p>
<p>The pharmacokinetics of aliskiren have not been investigated in patients &lt;18 years of age.</p>
<p><span class="Italics">Geriatri</span><span class="Italics">c Patients</span></p>
<p>The pharmacokinetics of aliskiren were studied in the elderly (≥65 years). Exposure (measured by AUC) is increased in elderly patients. Adjustment of the starting dose is not required in these patients [<span class="Italics">see Dosage and Administration (2)</span>].</p>
<p><span class="Italics">Race</span></p>
<p>Too few non-Caucasians have been studied with Tekturna HCT to assess pharmacokinetic differences among races. The pharmacokinetic differences among Blacks, Caucasians, and Japanese are minimal with aliskiren therapy.</p>
<p><span class="Italics">Renal I</span><span class="Italics">mpairment</span></p>
<p>The pharmacokinetics of aliskiren were evaluated in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Rate and extent of exposure (AUC and C<span class="Sub">max</span>) of aliskiren in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> did not show a consistent correlation with the severity of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Adjustment of the starting dose is not required in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, but Tekturna HCT is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee Dosage and </span><span class="Italics">Administration (2)</span><span class="Italics"> and Warnings and Precautions (5.4)</span><span class="Italics">]</span><span class="Italics">.</span></p>
<p><span class="Italics">Hepatic </span><span class="Italics">Impairment</span></p>
<p>The pharmacokinetics of aliskiren were not significantly affected in patients with mild-to-severe liver disease. Consequently, adjustment of the starting dose is not required in these patients [<span class="Italics">s</span><span class="Italics">ee Dosage and Administration (2)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold"> </span><span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First"><span class="Italics Underline">Tekturna </span><span class="Italics Underline">HCT</span></p>
<p>No carcinogenicity, mutagenicity or fertility studies have been conducted with Tekturna HCT. However, these studies have been conducted for aliskiren as well as hydrochlorothiazide alone.</p>
<p><span class="Italics Underline">Aliskiren</span></p>
<p>Carcinogenic potential was assessed in a 2-year rat study and a 6-month transgenic (rasH2) mouse study with aliskiren hemifumarate at oral doses of up to 1500 mg aliskiren/kg/day. Although there were no statistically significant increases in tumor incidence associated with exposure to aliskiren, mucosal epithelial <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> (with or without erosion/ulceration) was observed in the lower gastrointestinal tract at doses of 750 or more mg/kg/day in both species, with a colonic <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> identified in one rat and a cecal adenocarcinoma identified in another, rare tumors in the <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat studied. On a systemic exposure (AUC<span class="Sub">0-24hr</span>) basis, 1500 mg/kg/day in the rat is about 4 times and in the mouse about 1.5 times the maximum recommended human dose (300 mg aliskiren/day). Mucosal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the cecum or colon of rats was also observed at doses of 250 mg/kg/day (the lowest tested dose) as well as at higher doses in 4- and 13-week studies.</p>
<p>Aliskiren hemifumarate was devoid of genotoxic potential in the Ames reverse mutation assay with<span class="Italics"> S.</span> <span class="Italics">typhimurium</span> and <span class="Italics">E.</span> <span class="Italics">coli</span>, the in vitro Chinese hamster ovary cell chromosomal aberration assay, the in vitro<span class="Italics"> </span>Chinese hamster V79 cell gene mutation test and the in vivo mouse bone marrow micronucleus assay.</p>
<p>Fertility of male and female rats was unaffected at doses of up to 250 mg aliskiren/kg/day (8 times the maximum recommended human dose of 300 mg Tekturna/60 kg on a mg/m<span class="Sup">2</span> basis.</p>
<p><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p>Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of <span class="Italics">S.</span> <span class="Italics">typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mcgm/mL, and in the Aspergillums Nidulans nondisjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and 1.5 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold"> </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<p class="First"><span class="Italics Underline">Tekturna </span><span class="Italics Underline">HCT</span></p>
<p>In all clinical trials including over 6,200 patients, more than 2,700 patients were exposed to combinations of aliskiren and hydrochlorothiazide. The safety and efficacy of Tekturna HCT were evaluated in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in an 8-week, randomized, double-blind, placebo-controlled, parallel-group, 15-arm factorial trial (n=2762). Patients were randomized to receive various combinations of aliskiren (75 mg to 300 mg) plus hydrochlorothiazide (6.25 mg to 25 mg) once daily (without titrating up from monotherapy) and followed for blood pressure response. The combination of aliskiren and hydrochlorothiazide resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressure at trough of 10-14/5-7 mmHg at doses of 150-300 mg/12.5-25 mg, compared to 5-8/2-3 mmHg for aliskiren 150 mg to 300 mg and 6-7/2-3 mmHg for hydrochlorothiazide 12.5 mg to 25 mg, alone. Blood pressure reductions with the combinations were greater than the reductions with the monotherapies as shown in Table 1.</p>
<a name="ibb5b1bdc-e89f-4211-811d-562daae9ec2d"></a><table>
<caption><span>Table 1: Placebo-Subtracted Reductions in Seated Trough Cuff Blood Pressure in Combination with Hydrochlorothiazide</span></caption>
<col width="89">
<col width="144">
<col width="125">
<col width="125">
<col width="125">
<col width="125">
<tbody class="Headless">
<tr class="First">
<td align="center"></td>
<td align="center"></td>
<td align="center" colspan="4">Hydrochlorothiazide, mg</td>
</tr>
<tr>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center">0</td>
<td class="Toprule" align="center">6.25</td>
<td class="Toprule" align="center">12.5</td>
<td class="Toprule" align="center">25</td>
</tr>
<tr>
<td class="Toprule" align="center" valign="bottom">Aliskiren, mg</td>
<td class="Toprule" align="center" valign="bottom">Placebo Mean Change</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
</tr>
<tr>
<td class="Toprule" align="center">0</td>
<td class="Toprule" align="center" valign="bottom">7.5/6.9</td>
<td class="Toprule" align="center" valign="bottom">--</td>
<td class="Toprule" align="center" valign="bottom">3.5/2.1</td>
<td class="Toprule" align="center" valign="bottom">6.4/3.2</td>
<td class="Toprule" align="center" valign="bottom">6.8/2.4</td>
</tr>
<tr>
<td align="center">75</td>
<td align="center" valign="bottom">--</td>
<td align="center" valign="bottom">1.9/1.8</td>
<td align="center" valign="bottom">6.8/3.8</td>
<td align="center" valign="bottom">8.2/4.2</td>
<td align="center" valign="bottom">9.8/4.5</td>
</tr>
<tr>
<td align="center">150</td>
<td align="center" valign="bottom">--</td>
<td align="center" valign="bottom">4.8/2</td>
<td align="center" valign="bottom">7.8/3.4</td>
<td align="center" valign="bottom">10.1/5</td>
<td align="center" valign="bottom">12/5.7</td>
</tr>
<tr class="Last">
<td align="center">300</td>
<td align="center" valign="bottom">--</td>
<td align="center" valign="bottom">8.3/3.3</td>
<td align="center" valign="bottom">--</td>
<td align="center" valign="bottom">12.3/7</td>
<td align="center" valign="bottom">13.7/7.3</td>
</tr>
</tbody>
</table>
<p>The safety and efficacy of Tekturna HCT as initial therapy was evaluated in this trial. All patients randomized to the combination groups received the combination treatment of Tekturna HCT at assigned doses as initial therapy without titration from monotherapy. The figures [<span class="Italics">see Indications and Usage (1)</span>] display the probability that a patient will achieve systolic or diastolic blood pressure goal with Tekturna HCT 300/25 mg, based upon their baseline systolic or diastolic blood pressure. At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy.. </p>
<p>The antihypertensive effect of Tekturna HCT was largely manifested within 1 week. The maximum antihypertensive effect was generally attained after about 4 weeks of therapy.</p>
<p>One active-controlled trial investigated the addition of 300 mg aliskiren in obese hypertensive patients who did not respond adequately to hydrochlorothiazide 25 mg, and showed incremental decreases of systolic and diastolic blood pressure of approximately 7/4 mmHg.</p>
<p>In long-term follow-up studies (without placebo control) the effect of the combination of aliskiren and hydrochlorothiazide was maintained for over 1 year.</p>
<p>The antihypertensive effect was independent of age and gender. There were too few non-Caucasians to assess differences in blood pressure effects by race.</p>
<p><span class="Italics Underline">A</span><span class="Italics Underline">liskiren</span><span class="Italics Underline"> Monotherapy</span></p>
<p>The antihypertensive effects of aliskiren have been demonstrated in six randomized, double-blind, placebo-controlled, 8-week clinical trials in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The placebo response and placebo-subtracted changes from baseline in seated trough cuff blood pressure are shown in Table 2.</p>
<a name="i90da0305-66c2-4f13-8abf-72fe068b96f0"></a><table>
<caption><span>Table 2: Reductions in Seated Trough Cuff Blood Pressure in the Placebo-Controlled Studies of Aliskiren Monotherapy</span></caption>
<col width="49">
<col width="145">
<col width="129">
<col width="129">
<col width="129">
<col width="129">
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center"></td>
<td align="center" colspan="4">Aliskiren Daily Dose, mg</td>
</tr>
<tr>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center">75</td>
<td class="Toprule" align="center">150</td>
<td class="Toprule" align="center">300</td>
<td class="Toprule" align="center">600</td>
</tr>
<tr>
<td class="Toprule" align="center" valign="bottom">Study</td>
<td class="Toprule" align="center" valign="bottom">Placebo Mean Change</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
<td class="Toprule" align="center" valign="bottom">Placebo-subtracted</td>
</tr>
<tr>
<td class="Toprule" align="center">1</td>
<td class="Toprule" align="center">2.9/3.3</td>
<td class="Toprule" align="center">5.7/4*</td>
<td class="Toprule" align="center">5.9/4.5*</td>
<td class="Toprule" align="center">11.2/7.5*</td>
<td class="Toprule" align="center">--</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">5.3/6.3</td>
<td align="center">--</td>
<td align="center">6.1/2.9*</td>
<td align="center">10.5/5.4*</td>
<td align="center">10.4/5.2*</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">10/8.6</td>
<td align="center">2.2/1.7</td>
<td align="center">2.1/1.7</td>
<td align="center">5.1/3.7*</td>
<td align="center">--</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">7.5/6.9</td>
<td align="center">1.9/1.8</td>
<td align="center">4.8/2*</td>
<td align="center">8.3/3.3*</td>
<td align="center">--</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">3.8/4.9</td>
<td align="center">--</td>
<td align="center">9.3/5.4*</td>
<td align="center">10.9/6.2*</td>
<td align="center">12.1/7.6*</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">4.6/4.1</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">8.4/4.9<span class="Sup">†</span>
</td>
<td align="center">--</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="6">*p&lt;0.05 vs. placebo by ANCOVA with Dunnett’s procedure for multiple comparisons.<br><span class="Sup">†</span>p&lt;0.05 vs. placebo by ANCOVA for the pairwise comparison.</td></tr>
</tbody>
</table>
<p>The studies included approximately 2,730 patients given doses of 75 mg to 600 mg of aliskiren and 1,231 patients given placebo. As shown in Table 2, there is some increase in response with administered dose in all studies, with reasonable effects seen at 150 mg to 300 mg, and no clear further increase at 600 mg. A substantial proportion (85% to 90%) of the blood pressure lowering effect was observed within 2 weeks of treatment. Studies with ambulatory blood pressure monitoring showed reasonable control throughout the interdosing interval, e.g., the ratios of mean daytime to mean nighttime ambulatory BP ranged from 0.6 to 0.9.</p>
<p>Patients in the placebo-controlled trials continued open-label aliskiren for up to one year. A persistent blood pressure lowering effect was demonstrated by a randomized withdrawal study (patients randomized to continued drug or placebo), which showed a statistically significant difference between patients kept on aliskiren and those randomized to placebo. With cessation of treatment, blood pressure gradually returned toward baseline levels over a period of several weeks. There was no evidence of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> after abrupt cessation of therapy.</p>
<p>The effectiveness of<span class="Sup"> </span>aliskiren was demonstrated across all demographic subgroups, although Black patients tended to have smaller reductions in blood pressure than Caucasians and Asians, as has been seen with ACE inhibitors and ARBs.</p>
<p><span class="Italics Underline">Aliskiren in Combination with Other Antihypertensives</span></p>
<p><span class="Italics">V</span><span class="Italics">alsartan</span></p>
<p>Aliskiren 150 mg and 300 mg and valsartan 160 mg and 320 mg were studied alone and in combination in an 8-week, 1,797-patient, randomized, double-blind, placebo-controlled, parallel-group, 4-arm, dose-escalation study. The dosages of aliskiren and valsartan were started at 150 mg and 160 mg, respectively, and increased at four weeks to 300 mg and 320 mg, respectively. Seated trough cuff blood pressure was measured at baseline, 4, and 8 weeks. Blood pressure reductions with the combinations were greater than the reductions with the monotherapies as shown in Table 3.</p>
<a name="i08a9b281-f170-4025-8629-3b4d82643d51"></a><table>
<caption><span>Table 3: Placebo-Subtracted Reductions in Seated Trough Cuff Blood Pressure of Aliskiren in Combination with Valsartan</span></caption>
<col width="149">
<col width="178">
<col width="131">
<col width="140">
<col width="137">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" colspan="3">Valsartan, mg</td>
</tr>
<tr>
<td class="Toprule" align="center" valign="bottom">Aliskiren, mg</td>
<td class="Toprule" align="center" valign="bottom">Placebo Mean Change</td>
<td class="Toprule" align="center" valign="bottom">0</td>
<td class="Toprule" align="center" valign="bottom">160</td>
<td class="Toprule" align="center" valign="bottom">320</td>
</tr>
<tr>
<td class="Toprule" align="center">0</td>
<td class="Toprule" align="center" valign="bottom">4.6/4.1*</td>
<td class="Toprule" align="center">--</td>
<td class="Toprule" align="center">5.6/3.9</td>
<td class="Toprule" align="center">8.2/5.6</td>
</tr>
<tr>
<td align="center">150</td>
<td align="center" valign="bottom">--</td>
<td align="center">5.4/2.7</td>
<td align="center">10.0/5.7</td>
<td align="center">--</td>
</tr>
<tr>
<td align="center">300</td>
<td align="center" valign="bottom">--</td>
<td align="center">8.4/4.9</td>
<td align="center">--</td>
<td align="center">12.6/8.1</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5">* The placebo change is 5.2/4.8 for Week 4 endpoint which was used for the dose groups containing aliskiren 150 mg or valsartan 160 mg.</td></tr>
</tbody>
</table>
<p><span class="Bold Italics">ACE</span><span class="Bold Italics"> </span><span class="Bold Italics">I</span><span class="Bold Italics">nhibitors and Amlodipine</span></p>
<p>Aliskiren has not been studied when added to maximal doses of ACE inhibitors to determine whether aliskiren produces additional blood pressure reduction with a maximal dose of an ACE inhibitor. Aliskiren 150 mg provided additional blood pressure reduction when coadministered with amlodipine 5 mg in one study, but the combination was not statistically significantly better than amlodipine 10 mg.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold"> </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">Tekturna HCT is supplied as biconvex, ovaloid film-coated tablets.</p>
<p>All strengths are packaged in bottles as described below.</p>
<a name="ib0c125da-e136-4e55-8a65-2caf6dcd7b49"></a><table>
<caption><span>Table 4: Tekturna HCT Tablets Supply</span></caption>
<col width="127">
<col width="104">
<col width="80">
<col width="80">
<col width="104">
<col width="104">
<col width="135">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Tablet</span></td>
<td><span class="Bold">Color</span></td>
<td><span class="Bold">Imprint</span></td>
<td><span class="Bold">Imprint</span></td>
<td><span class="Bold">NDC #</span></td>
</tr>
<tr>
<td><span class="Bold">Aliskiren/HCTZ</span></td>
<td><br></td>
<td><span class="Bold">Side 1</span></td>
<td><span class="Bold">Side 2</span></td>
<td><span class="Bold">Bottle of 30</span></td>
<td><span class="Bold">Bottle of 90</span></td>
</tr>
<tr>
<td>150 mg/12.5 mg</td>
<td>White</td>
<td>NVR</td>
<td>LCI</td>
<td>54868-6041-0</td>
<td>--<br>
</td>
</tr>
<tr>
<td>300 mg/12.5 mg</td>
<td>Violet White</td>
<td>NVR</td>
<td>CVI</td>
<td>--</td>
<td>54868-6103-0<br>
</td>
</tr>
<tr class="Last">
<td>300 mg/25 mg<br>
</td>
<td>Light Yellow<br>
</td>
<td>NVR<br>
</td>
<td>CVV<br>
</td>
<td>--<br>
</td>
<td>54868-6194-0<br>
</td>
<td><br></td>
</tr>
</tbody>
</table>
<p><span>Storage</span></p>
<p>Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature].</p>
<p>Protect from moisture.</p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">17</span><span class="Bold"> </span><span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<p class="First">Healthcare professionals should instruct their patients to read the Patient Package Insert before starting Tekturna HCT and to reread each time the prescription is renewed. Patients should be instructed to inform their doctor or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens.</p>
<p><span class="Italics Underline">Pregnancy</span></p>
<p>Female patients of childbearing age should be told about the consequences of exposure to drugs that act on the renin-angiotensin system. Discuss other treatment options with female patients planning to become pregnant. These patients should be asked to report pregnancies to their physicians as soon as possible.</p>
<p><span class="Italics Underline">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></p>
<p>A patient receiving Tekturna HCT<span class="Sup"> </span>should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, Tekturna HCT should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Italics Underline">Potassium Supplements</span></p>
<p>A patient receiving Tekturna HCT<span class="Sup"> </span>should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</p>
<p><span class="Italics Underline">Relationship to Meals</span></p>
<p>Patients should establish a routine pattern for taking Tekturna HCT<span class="Sup"> </span>with regard to meals. High-fat meals decrease absorption substantially.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> (tek-turn-</span><span class="Bold">a </span><span class="Bold">HCT)</span></p>
<p><span class="Bold">(a</span><span class="Bold">liskiren</span><span class="Bold"> and </span><span class="Bold">hydrochlorothiazide</span><span class="Bold">, USP)</span></p>
<p><span class="Bold">Combination </span><span class="Bold">T</span><span class="Bold">ablets</span></p>
<p><span class="Bold">R</span><span class="Bold">ead the </span><span class="Bold">P</span><span class="Bold">atient </span><span class="Bold">I</span><span class="Bold">nformation </span><span class="Bold">that comes with </span><span class="Bold">Tekturna </span><span class="Bold">HCT </span><span class="Bold">before you start taking</span><span class="Bold"> </span><span class="Bold">it and each time you get a refill. There may be new information.</span><span class="Bold"> </span><span class="Bold">This leaf</span><span class="Bold">let does not take the place </span><span class="Bold">o</span><span class="Bold">f talking with your doctor about your condition and treatment.</span></p>
<p><span class="Bold">IMPORTANT WARNING: </span><span class="Bold">Tekturna </span><span class="Bold">HCT may harm an unborn baby, causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span><span class="Bold">If you get pregnant, stop taking </span><span class="Bold">Tekturna </span><span class="Bold">HCT </span><span class="Bold">and call your doctor right away. If you plan to become pregnant, talk to your doctor about other </span><span class="Bold">medicines to treat your high blood pressure</span><span class="Bold"> before taking </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">.</span></p>
<p><span class="Bold">What </span><span class="Bold">i</span><span class="Bold">s </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">?</span></p>
<p>Tekturna HCT<span class="Sup"> </span>contains two prescription medicines in one tablet that work together to lower blood pressure. It contains:</p>
<ul>
<li>aliskiren (Tekturna), a direct renin inhibitor (DRI)<br>
</li>
<li>hydrochlorothiazide, a diuretic (water pill)</li>
</ul>
<p>Aliskiren (Tekturna) reduces the effect of renin, and the harmful process that narrows blood vessels. Aliskiren also helps blood vessels relax and widen so blood pressure is lower. Hydrochlorothiazide reduces the amount of salt and water in your body so your blood pressure is lower. </p>
<p>Tekturna HCT may be used to lower high blood pressure in adults</p>
<ul>
<li>when one medicine to lower high blood pressure is not enough<br>
</li>
<li>as the first medicine to lower high blood pressure if your doctor decides that you are likely to need more than one medicine </li>
</ul>
<p>Tekturna HCT has not been studied in children under 18 years of age.</p>
<p>Your doctor may prescribe other medicines for you to take along with Tekturna HCT to treat your high blood pressure.</p>
<p><span class="Bold">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span></p>
<p>Blood pressure is the force that pushes the blood through your blood vessels to all the organs of your body. You have high blood pressure when the force of your blood moving through your blood vessels is too great. One cause of high blood pressure is renin, a chemical in the body that starts a process that makes blood vessels narrow, leading to high blood pressure.</p>
<p>Tekturna HCT reduces high blood pressure. Medicines that lower your blood pressure lower your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems.</p>
<p><span class="Bold">Who </span><span class="Bold">s</span><span class="Bold">hould </span><span class="Bold">n</span><span class="Bold">ot </span><span class="Bold">t</span><span class="Bold">ake </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">?</span></p>
<ul>
<li>
<span class="Bold">If you get pregnant</span>, <span class="Bold">stop taking </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Sup"> </span><span class="Bold">and</span><span class="Bold"> call your doctor right away. If you plan to become pregnant, talk to your doctor about other treatment options for your high blood pressure.</span><br>
</li>
<li>
<span class="Bold">Do </span><span class="Bold">not </span><span class="Bold">take </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Sup"> </span><span class="Bold">if you </span><span class="Bold">make very little or no urine due to</span><span class="Bold"> kidney problems</span><span class="Bold">.</span><br>
</li>
<li>
<span class="Bold">Do not take </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold"> if</span><span class="Bold"> you are aller</span><span class="Bold">gic to any of its ingredients.</span><span class="Bold"> See the end of this leaflet for a complete list of the ingredients in </span><span class="Bold">Tekturna </span><span class="Bold">HCT.</span>
</li>
</ul>
<p><span class="Bold">What </span><span class="Bold">s</span><span class="Bold">hould I </span><span class="Bold">t</span><span class="Bold">ell </span><span class="Bold">m</span><span class="Bold">y </span><span class="Bold">d</span><span class="Bold">octor </span><span class="Bold">be</span><span class="Bold">fore </span><span class="Bold">t</span><span class="Bold">aking </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions, including whether you</span><span class="Bold">:</span></p>
<ul>
<li>are pregnant or planning to become pregnant. See IMPORTANT WARNING.<br>
</li>
<li>have any allergies or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span><br>
</li>
<li>have kidney problems<br>
</li>
<li>have liver problems<br>
</li>
<li>have <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (SLE). Tekturna HCT can make your SLE active or worse.<br>
</li>
<li>have ever had a reaction called <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, to an ACE inhibitor medicine. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> causes <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, throat, arms and legs, and may cause <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.<br>
</li>
<li>are breast-feeding<span class="Bold">.</span><span class="Bold"> </span>It is not known if Tekturna HCT<span class="Sup"> </span>passes into your breast milk.<br>
</li>
<li>Take Tekturna HCT exactly as prescribed by your doctor. It is important to take Tekturna HCT every day to control your blood pressure.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take </span>including prescription and nonprescription medicines, vitamins and herbal supplements. Especially tell your doctor if you are taking:</p>
<ul>
<li>other medicines for high blood pressure or a heart problem<br>
</li>
<li>atorvastatin (medicine to lower <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood)<br>
</li>
<li>water pills (also called “diuretics?)<br>
</li>
<li>medicines for treating fungus or <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span><br>
</li>
<li>cyclosporine (a medicine used to suppress the immune system)<br>
</li>
<li>potassium-containing medicines, potassium supplements, or salt substitutes containing potassium<br>
</li>
<li>cholestyramine (for example; Questran, Questran Light, Cholestyramine Light, Locholest Light, Locholest, Prevalite) (medicines to lower the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood)<br>
</li>
<li>colestipol (for example; Colestipol hydrochloride, Colestid, Flavored Colestid) (medicines to lower the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood)<br>
</li>
<li>potassium supplements<br>
</li>
<li>medicines to treat <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, including insulin<br>
</li>
<li>lithium, a medicine used in some types of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Do not take Tekturna HCT if you are taking lithium.<br>
</li>
<li>Nonsteroidal anti-inflammatory (NSAIDs) medicines. Ask your doctor if you are not sure if you are taking one of these medicines.<br>
</li>
<li>blood thinners<br>
</li>
<li>barbiturate or narcotic medicines. Ask your doctor if you are not sure if you are taking one of these medicines.</li>
</ul>
<p>Your doctor or pharmacist will know what medicines are safe to take together. Know your medicines. Keep a list of your medicines and show it to your doctor or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How </span><span class="Bold">s</span><span class="Bold">hould I </span><span class="Bold">t</span><span class="Bold">ake </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">?</span></p>
<ul>
<li>Take Tekturna HCT<span class="Sup"> </span>once each day, about the same time each day.<br>
</li>
<li>Take Tekturna HCT the same way everyday, either with or without a meal.<br>
</li>
<li>Your doctor may change your dose of Tekturna HCT if needed.<br>
</li>
<li>If you miss a dose of Tekturna HCT, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at your regular time.<br>
</li>
<li>If you take too much Tekturna HCT, call your doctor or a Poison Control Center, or go to the nearest hospital emergency room.</li>
</ul>
<p><span class="Bold">What </span><span class="Bold">a</span><span class="Bold">re </span><span class="Bold">t</span><span class="Bold">he </span><span class="Bold">p</span><span class="Bold">ossible </span><span class="Bold">s</span><span class="Bold">ide </span><span class="Bold">e</span><span class="Bold">ffects </span><span class="Bold">o</span><span class="Bold">f </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">?</span></p>
<p>Tekturna HCT may cause serious side effects:</p>
<ul>
<li>
<span class="Bold">Injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby.</span> See IMPORTANT WARNING.<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>). </span>Your blood pressure may get too low if you also take water pills, are on a low-salt diet, get dialysis treatments, have heart problems, or get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Drinking alcohol and taking certain medicines (barbiturates or narcotics) can cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> to get worse. Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy, and call your doctor right away.<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>.</span> Aliskiren in Tekturna HCT can cause <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, throat, arms and legs, or the whole body. Get medical help right away and tell your doctor if you get any one or more of these symptoms. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> can happen at any time while you are taking Tekturna HCT.<br>
</li>
<li>
<span class="Bold">Active or worsened <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span> (SLE).</span> If you have SLE, tell your doctor right away if you get any new or worse symptoms.</li>
</ul>
<p><span class="Bold">Common s</span><span class="Bold">ide </span><span class="Bold">e</span><span class="Bold">ffects </span><span class="Bold">of </span><span class="Bold">Tekturna </span><span class="Bold">HCT include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><br>
</li>
<li>flu-like symptoms<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
</ul>
<p><span class="Bold">Other less common side effects</span><span class="Bold"> include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</span></p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Tekturna HCT. For a complete list of side effects, ask your doctor or pharmacist.</p>
<p><span class="Bold">How </span><span class="Bold">d</span><span class="Bold">o I </span><span class="Bold">s</span><span class="Bold">tore </span><span class="Bold">Tekturna </span><span class="Bold">HCT?</span></p>
<ul>
<li>Store Tekturna HCT<span class="Sup"> </span>tablets at room temperature between 59<span class="Sup">o</span>F-86<span class="Sup">o</span>F (15<span class="Sup">o</span>C-30<span class="Sup">o</span>C).<br>
</li>
<li>Keep Tekturna HCT<span class="Sup"> </span>in the original prescription bottle in a dry place. Do not remove the desiccant (drying agent) from the bottle.</li>
</ul>
<p><span class="Bold">Keep </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold"><span class="Sup"> </span></span><span class="Bold">and</span><span class="Bold"> all medicines out of the reach of children.</span></p>
<p><span class="Bold">General </span><span class="Bold">i</span><span class="Bold">nformation </span><span class="Bold">a</span><span class="Bold">bout </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span></p>
<p>Medicines are sometimes prescribed for conditions not listed in the patient information leaflet. Do not take Tekturna HCT for a condition for which it was not prescribed. Do not give Tekturna HCT<span class="Sup"> </span>to other people, even if they have the same condition or symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about Tekturna HCT. If you have questions about Tekturna HCT talk with your doctor. You can ask your doctor or pharmacist for information that is written for healthcare professionals.</p>
<p><span class="Bold">For more information about </span><span class="Bold">Tekturna </span><span class="Bold">HCT</span><span class="Bold">, visit</span><span class="Bold"> </span><span class="Bold">www.TekturnaHCT.com</span><span class="Bold">, or call </span><span class="Bold">1</span>-<span class="Bold">888</span>-<span class="Bold">669</span>-<span class="Bold">6682</span><span class="Bold">.</span></p>
<p><span class="Bold">What are the ingredients in </span><span class="Bold">Tekturna </span><span class="Bold">HCT?</span></p>
<p>Active ingredients: Aliskiren and hydrochlorothiazide</p>
<p>Inactive ingredients: Colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxide colorants, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, talc, and titanium dioxide, and wheat starch</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1</span><span class="Bold">-800</span><span class="Bold">-FDA</span><span class="Bold">-1088.</span></p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p>REV: February 2010
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	T2010-16/T2010-17</p>
<p>© Novartis</p>
<br><p><br></p>
<p>Relabeling of "Additional Barcode" by:<br>Physicians Total Care, Inc.<br>Tulsa, OK    74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Package Label – </span><span class="Bold">150 </span><span class="Bold">mg / </span><span class="Bold">1</span><span class="Bold">2</span><span class="Bold">.</span><span class="Bold">5 mg</span></p>
<p>Rx Only             <br></p>
<p>Tektruna HCT® </p>
<p>(aliskiren and hydrochlorothiazide)</p>
<div class="Figure"><img alt="image of 150 mg / 12.5 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=package%20label%2001.jpg"></div>
<p><br></p>
<p><span class="Bold">Package Label – 300</span><span class="Bold"><span class="Bold">mg / </span><span class="Bold">1</span><span class="Bold">2</span><span class="Bold">.</span><span class="Bold">5 mg</span></span></p>
<p>Rx Only             <br></p>
<p>Tektruna HCT® </p>
<p>(aliskiren and hydrochlorothiazide) <br></p>
<div class="Figure"><img alt="image of 300 mg / 12.5 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=package%20label%2002.jpg"></div>
<p></p>
<p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">Package Label – </span><span class="Bold">300 mg / 25 
mg</span></p>
<p>Rx Only             <br></p>
<p>Tektruna HCT® </p>
<p>(aliskiren and hydrochlorothiazide) </p>
<div class="Figure"><img alt="image of 300 mg/ 25 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=40d12d97-152d-4fea-bc59-b69e5c29fde2&amp;name=package%20label%2003.jpg"></div>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEKTURNA HCT 		
					</strong><br><span class="contentTableReg">aliskiren hemifumarate and hydrochlorothiazide    tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6041(NDC:0078-0521)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALISKIREN HEMIFUMARATE</strong> (ALISKIREN) </td>
<td class="formItem">ALISKIREN HEMIFUMARATE</td>
<td class="formItem">150 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, WHEAT</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (light yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;CVV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6041-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022107</td>
<td class="formItem">06/15/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEKTURNA HCT 		
					</strong><br><span class="contentTableReg">aliskiren hemifumarate and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6103(NDC:0078-0523)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALISKIREN HEMIFUMARATE</strong> (ALISKIREN) </td>
<td class="formItem">ALISKIREN HEMIFUMARATE</td>
<td class="formItem">300 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, WHEAT</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (violet white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;CVI</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6103-0</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022107</td>
<td class="formItem">04/13/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEKTURNA HCT 		
					</strong><br><span class="contentTableReg">aliskiren hemifumarate and hydrochlorothiazide    tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6194(NDC:0078-0524)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALISKIREN HEMIFUMARATE</strong> (ALISKIREN) </td>
<td class="formItem">ALISKIREN HEMIFUMARATE</td>
<td class="formItem">300 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, WHEAT</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (light yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;CW</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6194-0</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022107</td>
<td class="formItem">11/03/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3a41bc46-8bba-4c61-9299-3108f05a0d4d</div>
<div>Set id: 40d12d97-152d-4fea-bc59-b69e5c29fde2</div>
<div>Version: 3</div>
<div>Effective Time: 20090925</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
